Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.8 million.

  • Aclaris Therapeutics' Other Non-Current Assets fell 1190.55% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 1190.55%. This contributed to the annual value of $3.1 million for FY2024, which is 2626.26% down from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Other Non-Current Assets is $2.8 million, which was down 1190.55% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Other Non-Current Assets peaked at $4.2 million during Q4 2023, and registered a low of $2.7 million during Q3 2023.
  • In the last 5 years, Aclaris Therapeutics' Other Non-Current Assets had a median value of $3.2 million in 2024 and averaged $3.3 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Other Non-Current Assets surged by 5219.62% in 2023 and then plummeted by 2626.26% in 2024.
  • Aclaris Therapeutics' Other Non-Current Assets (Quarter) stood at $3.6 million in 2021, then fell by 23.13% to $2.7 million in 2022, then soared by 52.2% to $4.2 million in 2023, then dropped by 26.26% to $3.1 million in 2024, then dropped by 7.57% to $2.8 million in 2025.
  • Its Other Non-Current Assets stands at $2.8 million for Q3 2025, versus $3.0 million for Q2 2025 and $3.2 million for Q1 2025.